Ulcerative colitis (UC) is an inflammatory bowel disease. It causes irritation, inflammation, and ulcers in the lining of the large intestine.
Ulcerative Colitis Research Studies
Investigators
Open Research Studies for Ulcerative Colitis
Seres Eco-Reset
Enrolling: Yes
Principle Investigator: Monika Fischer, MD
Duration: 17 Months (Approx. 7 clinic visits + two colonoscopies)
Patient Population: Adult patients with mild to moderate Ulcerative Colitis
Study Intervention: SER-287 Investigational Microbiome Drug
Possibility of Placebo: 1 in 3
Quasar
Enrolling: Will Begin Enrollment near the end of 2020
Principle Investigator: Sashidhar Sagi, MD
Duration: 15 months (with the option of an additional 2 years of treatment after)
Patient Population: Adult patients with moderate to severe Ulcerative Colitis
Study Intervention: Guselkumab
Possibility of Placebo: 1 in 3
SPARC IBD
Enrolling: On Hold
Principle Investigator: Matthew Bohm, DO
Duration: All bio-specimen collections and chart reviews will continue until 2026
Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis
Study Intervention: Medical chart reviews and biological specimen collection.
TOUR
Enrolling: Yes
Principle Investigator: Monika Fischer, MD
Duration: 12 months
Patient Population: Any patient with Ulcerative Colitis starting Tofacitinib (Xeljanz) for the first time as part of their standard treatment for UC.
Study Intervention: Medical chart review and e-mail patient questionnaires (Enrollment and participation is done via phone.)